<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Old, Frail and on Costly Drugs</title>
    <meta content="LTR004545" name="slug"/>
    <meta content="13" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Thursday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="28" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="5" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1214615"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Medicine and Health</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Health Insurance</classifier>
        <classifier class="indexing_service" type="descriptor">Aged</classifier>
        <classifier class="indexing_service" type="descriptor">Medicare</classifier>
        <classifier class="indexing_service" type="descriptor">Prices (Fares, Fees and Rates)</classifier>
        <location class="indexing_service">Nevada</location>
        <person class="indexing_service">Kaiser, Robert M</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/North America</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/North America/United States</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/North America/United States/Nevada</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicare</classifier>
        <classifier class="online_producer" type="general_descriptor">Prices (Fares, Fees and Rates)</classifier>
        <classifier class="online_producer" type="general_descriptor">Health Insurance and Managed Care</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Aged</classifier>
        <classifier class="online_producer" type="general_descriptor">Insurance</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000713T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C0CE0DA1F38F930A25754C0A9669C8B63" item-length="194" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Old, Frail and on Costly Drugs</hl1>
      </hedline>
      <abstract>
        <p>Dr Robert M Kaiser letter, commenting on July 8 article, says it is not surprising that Nevada's prescription drug program is floundering since insurance companies have no incentive to offer coverage for those who need it most</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>It is hardly surprising that Nevada's prescription drug program for the elderly is floundering from the start (''Ominous Start for a Drug Prescription Plan for the Elderly,'' news article, July 8). Insurance companies have no incentive to offer coverage for those patients who need it most: those with high use and high costs. Even with the available subsidies from the state, there are insufficient economies of scale to make the program profitable.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>It is hardly surprising that Nevada's prescription drug program for the elderly is floundering from the start (''Ominous Start for a Drug Prescription Plan for the Elderly,'' news article, July 8). Insurance companies have no incentive to offer coverage for those patients who need it most: those with high use and high costs. Even with the available subsidies from the state, there are insufficient economies of scale to make the program profitable.</p>
        <p>The program also suffers from a fatal philosophical flaw. It depends upon money received from tobacco companies rather than from taxpayers or healthy payers of insurance premiums. A successful program over the long term depends upon the assumption of financial responsibility by the American public.</p>
        <p>ROBERT M. KAISER, M.D.  Durham, N.C., July 9, 2000</p>
        <p>The writer is a fellow in geriatrics at Duke University.</p>
      </block>
    </body.content>
  </body>
</nitf>
